The nation of Zimbabwe has turned down a significant US health deal worth 367 million US dollars (272 million pounds) over five years because of the United States' request for confidential biological samples.
The decision came to light following a government memo from December was disclosed, indicating that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesperson has since clarified that the United States was seeking health data for research and commercial gain but refused to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had donated over $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further dialogue to reach a agreement suitable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Background
Zimbabwe's decision follows a comparable situation in Kenya, where a court blocked a related health funding agreement following legal challenges were filed about the security of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
As per statements, 16 nations in Africa have to date agreed to similar health pacts, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to surrender its biological resources and data indefinitely, without any equivalent promise of access to any medical innovations – like new medicines or tests – that could be developed from that provided information," he stated.
"Effectively, our nation would supply the raw materials for medical research without any assurance that the resulting innovations would be available to our people should a new health crisis emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of one-on-one deals were disrupting structures previously established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to manage potential global health emergencies.
"This system is designed to guarantee that when a nation contributes its samples, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how future collaboration might be arranged in a way that respects the sovereignty and dignity of each country."
Health Experts Reaction
A leading public health body expressed it understood the official position, but urged that negotiations need to persist given that a large portion of the nation's Aids initiatives were funded by external financing.
"In cases where specific concerns exist, including those involving data governance or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," it said.
This impasse underscores the ongoing challenges between receiving crucial foreign assistance and safeguarding a country's data in an increasingly data-driven world.